BioMarin

BioMarin Pharmaceutical Inc.

Company type	Public
Traded as	NASDAQ: BMRN
Industry	Biotechnology
Founded	1997
Founder	Christopher Starr, Ph.D., Grant W. Denison Jr.
Key people	Jean-Jacques Bienaimé (CEO)
Products	Pharmaceuticals
Revenue	$1.86 billion (2020)
Number of employees	3,000 (2020)
Website	www.biomarin.com

BioMarin Pharmaceutical Inc. is an American biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. The company is particularly known for its focus on rare genetic disorders.

History

BioMarin was founded in 1997 by Christopher Starr and Grant W. Denison Jr. in Novato, California. The company was established with the goal of developing therapies for rare genetic diseases, a field that was largely underserved at the time. BioMarin's first product, Aldurazyme, was developed in collaboration with Genzyme Corporation and was approved by the FDA in 2003 for the treatment of Mucopolysaccharidosis I.

Products

BioMarin has developed several products that have been approved for use in various countries. Some of the key products include:

• Aldurazyme - Used for the treatment of Mucopolysaccharidosis I.
• Naglazyme - Approved for the treatment of Mucopolysaccharidosis VI.
• Kuvan - Used to treat Phenylketonuria (PKU).
• Vimizim - Approved for the treatment of Mucopolysaccharidosis IVA.
• Brineura - Used for the treatment of CLN2 disease, a form of Batten disease.

Research and Development

BioMarin is heavily invested in research and development, focusing on therapies for rare genetic diseases. The company has a robust pipeline of investigational drugs, including gene therapies and enzyme replacement therapies. BioMarin's R&D efforts are aimed at addressing unmet medical needs and improving the quality of life for patients with rare conditions.

Corporate Structure

BioMarin is headquartered in San Rafael, California, and operates globally with offices and facilities in various countries. The company is publicly traded on the NASDAQ under the ticker symbol BMRN.

Impact and Recognition

BioMarin has been recognized for its contributions to the field of biotechnology and its commitment to developing treatments for rare diseases. The company's innovative approach and successful product launches have made it a leader in the biopharmaceutical industry.

Also see

• Genzyme Corporation
• Biotechnology
• Rare diseases
• Gene therapy
• Enzyme replacement therapy